ArticleBiomolecules2026
Mesenchymal Stem Cell Exosome-Mediated Delivery of Paclitaxel for Pancreatic Cancer Therapy.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies, with limited response to conventional chemotherapies such as paclitaxel (PTX) due to poor solubility, low bioavailability, and systemic toxicity. To address these limitations, this study explores mesenchymal stem cell (MSC)-derived exosomes as biocompatible, tumor-homing nanocarriers for PTX delivery. Exosomes were isolated from MSC-conditioned media using ultracentrifugation and tangential flow filtration (TFF), with TFF yielding 8 to 9-fold higher exosome recovery. Flow cytometry confirmed the presence of exosomal (CD63, CD81) and MSC (CD90) surface markers, while transmission electron microscopy and dynamic light scattering revealed spherical vesicles averaging ~160 nm in diameter with a zeta potential of approximately -28 mV. PTX was loaded into exosomes using ultrasonication, achieving an encapsulation efficiency of 31.3 ± 2.0%, and release studies showed an initial burst within 24 h followed by sustained release over 7 days. Blank exosomes exhibited no cytotoxicity toward PANC-1, BxPC-3, and HPNE cells, confirming their excellent biocompatibility. In contrast, PTX-loaded exosomes significantly enhanced cytotoxicity compared to free PTX, reducing IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.